Phase I/II clinical trial of regorafenib plus durvalumab (MEDI4736) in patients with chemotherapy-refractory advanced biliary tract cancers.

被引：0
|
作者：
Al-Rajabi, Raed Moh'd Taiseer
Kasi, Anup
Baranda, Joaquina Celebre
Saeed, Anwaar
Li, Haoran
Bruey, Collin
Best, Shaun
Phadnis, Milind A.
Sun, Weijing
机构：
[1] Univ Kansas, Canc Ctr, Westwood, KS USA
[2] Univ Kansas, Canc Ctr, Fairway, KS USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Univ Kansas, Med Ctr, Kansas City, KS USA
[5] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-237-2581-144; 261-492-3532-2370-7650-2700; 613-225-313; 298-145-222-184-1022-9122; 261-492-2769; 281-5277-2560; 283-2494; 7; 4; 3; 2; 250; 2018; 91; 176; 62; 6; 1; 38092-18909; 38116-38094-8; 5;
D O I：
10.1200/JCO.2024.42.3_suppl.TPS581
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS581
引用
收藏
页码：TPS581 / TPS581
页数：1
相关论文
共 50 条
  • [31] Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer
    O'Bryan, James
    Yin, Chao
    Weinberg, Benjamin Adam
    Noel, Marcus Smith
    Mukherji, Reetu
    Kulasekaran, Monika
    Agarwal, Seema
    Kupfer, Gary
    Wang, Hongkun
    Hartley, Marion L.
    Marshall, John
    He, Aiwu Ruth
    Asco Authors Grp
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] SELECT-4: Phase I dose escalation trial of selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.
    Janne, Pasi A.
    Ghiorghiu, Dana C.
    Smith, Paul D.
    Belli, Riccardo
    Dennis, Phillip A.
    Mariani, Gabriella Lucia
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) plus BEVACIZUMAB (BEV) IN BEV-NAIVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
    Reardon, David
    Kaley, Thomas
    Dietrich, Jorg
    Clarke, Jennifer
    Dunn, Gavin
    Lim, Michael
    Cloughesy, Tim
    Gan, Hui
    Park, Andrew
    Schwarzenberger, Paul
    Ricciardi, Toni
    Macri, Mary
    Ryan, Aileen
    Venhaus, Ralph
    NEURO-ONCOLOGY, 2018, 20 : 10 - 10
  • [34] A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers
    Den Linger, Crystal S.
    Meropol, Neal J.
    Li, Tianyu
    Lewis, Nancy L.
    Engstrom, Paul F.
    Weiner, Louis M.
    Cheng, Jonathan D.
    Alpaugh, R. Katherine
    Cooper, Harry
    Wright, John J.
    Cohen, Steven J.
    CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 81 - 86
  • [35] Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma
    Chakrabarti, Sakti
    Zemla, Tyler J.
    Ahn, Daniel H.
    Ou, Fang-Shu
    Fruth, Briant
    Borad, Mitesh J.
    Hartgers, Mindy L.
    Wessling, Jaclynn
    Walkes, Rachel L.
    Alberts, Steven R.
    McWilliams, Robert R.
    Liu, Minetta C.
    Durgin, Lori M.
    Bekaii-Saab, Tanios S.
    Mahipal, Amit
    ONCOLOGIST, 2020, 25 (05): : 380 - +
  • [36] A phase 2 trial of regorafenib as a single agent in patients with chemotherapy refractory advanced and metastatic biliary adenocarcinoma/cholangioca
    Sun, Weijing
    Normolle, Daniel Paul
    Bahary, Nathan
    Ohr, James
    Lembersky, Barry C.
    Patel, Krishna
    Patel, Anuj K.
    Lee, James J.
    Chu, Edward
    Streeter, Natalie
    Drummond, Summer
    Morcos, John P.
    Sulecki, Matthew Gerard
    Geller, David A.
    Marsh, J. Wallis
    Tsung, Allan
    Zeh, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] A phase II trial of regorafenib as a single agent in patients with advanced and metastatic biliary tract carcinoma and first-line chemotherapy failure
    Patel, Anuj Kishor
    Stoller, Ronald G.
    Rhee, John C.
    Lembersky, Barry C.
    Ohr, James
    Lee, James J.
    Bahary, Nathan
    Chu, Edward
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
    Peters, S.
    Antonia, S.
    Goldberg, S. B.
    Heymach, J. V.
    Kim, E. S.
    Nakagawa, K.
    Papadimitrakopoulou, V.
    Mukhopadhyay, P.
    McIntosh, S.
    Rizvi, N. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S139 - S140
  • [39] Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
    Anwaar Saeed
    Robin Park
    Harsh Pathak
    Ayah Nedal Al-Bzour
    Junqiang Dai
    Milind Phadnis
    Raed Al-Rajabi
    Anup Kasi
    Joaquina Baranda
    Weijing Sun
    Stephen Williamson
    Yu-Chiao Chiu
    Hatice Ulku Osmanbeyoglu
    Rashna Madan
    Hassan Abushukair
    Kelly Mulvaney
    Andrew K. Godwin
    Azhar Saeed
    Nature Communications, 15
  • [40] A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
    Ko, Andrew H.
    Bekaii-Saab, Tanios
    Van Ziffle, Jessica
    Mirzoeva, Olga M.
    Joseph, Nancy M.
    Talasaz, AmirAli
    Kuhn, Peter
    Tempero, Margaret A.
    Collisson, Eric A.
    Kelley, R. Kate
    Venook, Alan P.
    Dito, Elizabeth
    Ong, Anna
    Ziyeh, Sharvina
    Courtin, Ryan
    Linetskaya, Regina
    Tahiri, Sanaa
    Korn, W. Michael
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 61 - 68
12345